108 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
products, if any, statements regarding the potential attributes and benefits of our product candidates, including indications, dosing and treatment … , or efficacy concerns, or any other reasons), risks related to the potential benefits and risks related to our current collaborations, including our plans
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
. Benefits and expenses Benefits To align to market practice and help enable Board members fulfil their duties. The Company provides administrative support … across the Company. Benefits Competitive benefits are provided to attract and retain executives, contribute towards retirement planning and provide
6-K
EX-99.3
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
by the Company upon each exercise of the Warrant shall be fully paid up and shall have the same rights and benefits as, and rank pari passu in all respects
6-K
EX-99.7
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Warrant B shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlement to dividends and other distributions … shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlement to dividends and other distributions
6-K
EX-99.4
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
be fully paid up and shall have the same rights and benefits as, and rank pari passu in all respects including as to entitlement to dividends and other
6-K
EX-99.5
30q40 ej76g8shlex
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.14
kbrj8wo
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
EX-99.1
zn5zbkdr
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
6-K
EX-99.1
b7dackp6wbfp
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
txmdyliu nza3jud
4 Jan 24
Current report (foreign)
5:32pm
6-K
EX-99.1
gdjokjx0 ehes
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
EX-99.1
yi195j49s zk78
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
S-8
EX-99.1
igj631ax9 oh9euj
4 Dec 23
Registration of securities for employees
5:16pm
S-8
EX-99.2
k8cu3gehs y79zccf
4 Dec 23
Registration of securities for employees
5:16pm
6-K
EX-99.1
0oc bcrj4y
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am